Xintong Medical-B

MicroPort CardioFlow Medtech Corporation is a leading medical device company specializing in the development and commercialization of transcatheter and surgical solutions for structural heart diseases. Spun off from MicroPort Scientific, the company is a dominant player in China's transcatheter aortic valve implantation (TAVI) market with its flagship VitaFlow series, including the VitaFlow and VitaFlow Liberty systems. Its portfolio extends to transcatheter mitral valve (TMV) and tricuspid valve (TTV) therapies, as well as procedural accessories like balloon catheters and embolic protection devices. Following a strategic merger with MicroPort CRM in 2025, the company has expanded its focus to include cardiac rhythm management and heart failure care, aiming to provide an integrated platform for comprehensive cardiovascular management.